Refine by
Cancer Risk Articles & Analysis
169 news found
Puerto Rico’s leading environmental and industrial hygiene consulting firm, Zimmetry Environmental, is marking National Cancer Prevention Month by raising awareness about the critical role environmental exposures play in cancer risk. ...
Forever chemicals – also known as per and poly fluoralkyl substances (PFAS) – are a family of different compounds so called because of how they persist in the environment, with many (such as perfluorooctanoic acid and perfluorooctane sulfonic acid) associated with adverse effects in both animals and people. PFAS enjoy widespread use in a range of different industries, featuring in ...
Some of these same carcinogens could even be an exposure risk for anyone entering a building or worksite. In the United States, the Centers for Disease Control and Prevention (CDC) reports that more men and women die in this country from lung cancer than from any other type of cancer. This correlates to approximately 136,000 annual deaths and ...
” Now hospitals can use the technology while we learn more about the long term (>10 years) outcomes of using the NanoKnife System for prostate cancer as they collect their audit data. When men are diagnosed with prostate cancer it is graded as Low, Intermediate or High risk. As documented in the NICE guidance, Low risk ...
We are pleased to offer congratulations to Professor Jurgen Fütterer and his team at Radboud University Medical Centre in the Netherlands, for having successfully secured €3.8 million from the Dutch National Health Care Institute and ZonMw towards the ENFORCE trial, a fully funded Randomised Controled Trial for Focal Therapy which incorporates the NanoKnife System as a treatment option ...
Bayer is progressing novel research around its prostate cancer treatment darolutamide. The presentation highlights the synergistic anti-cancer effects of a PSMA (prostate-specific membrane antigen)-actinium-225 conjugate in combination with darolutamide in preclinical prostate cancer models. Darolutamide, which is jointly developed by Bayer and ...
ByBayer AG
Phase III study ARASTEP initiated in hormone-sensitive prostate cancer, in patients with high-risk biochemical recurrence (BCR) who have no evidence of metastatic disease by conventional imaging and a positive PSMA PET CT at baseline Fifth major clinical trial for androgen receptor inhibitor (ARi) darolutamide, covering prostate cancer from ...
ByBayer AG
Nubeqa is already approved in China for the treatment of patients with non-metastatic castration-resistant prostate cancer (nmCRPC), who are at high risk of developing metastatic disease. ...
ByBayer AG
Nubeqa is already approved for the treatment of patients with non-metastatic castration-resistant prostate cancer (nmCRPC), who are at high risk of developing metastatic disease. ...
ByBayer AG
The MHLW approval is based on the positive results from the Phase III ARASENS trial, which demonstrated that darolutamide plus androgen deprivation therapy (ADT) in combination with docetaxel significantly reduced the risk of death by 32.5% compared to ADT with docetaxel, in patients with metastatic hormone-sensitive prostate cancer (mHSPC). ...
ByBayer AG
For men, it is the second-most diagnosed cancer globally after lung cancer. Advanced age, ethnicity, obesity and family history are known risk factors. ...
New subgroup analysis from Phase III ARASENS trial shows that darolutamide plus androgen deprivation therapy (ADT) in combination with docetaxel increased overall survival (OS) and improved key clinically relevant endpoints in patients with various types of metastatic disease burden and risk, compared to ADT with docetaxel alone Favorable safety profile of darolutamide plus ...
ByBayer AG
The miR Sentinel™ Prostate Cancer Test is a standalone, non-invasive liquid biopsy urine test that can, from a single urine specimen, accurately detect molecular evidence of prostate cancer and, if cancer is detected, classify the severity, or the risk grade, of the malignancy. ...
Darolutamide is already approved under the brand name Nubeqa™ for the treatment of patients with non-metastatic castration-resistant prostate cancer (nmCRPC), who are at high risk of developing metastatic disease. ...
ByBayer AG
The lung cancer screening demonstration project led by Dr Simon Martel, pulmonologist at the Quebec Heart and Lung Institute (Institut Universitaire de Cardiologie et Pneumologie de Québec-Université Laval – IUCPQ-UL) is intended to combine BioMark’s metabolomics liquid biopsy test with radiomics and genetics biomarkers to help at-risk ...
” The product labels of all JAK inhibitors will be updated to include a precautionary approach for patients aged 65 years or above, those at increased risk of major cardiovascular problems (such as heart attack or stroke), those who smoke or have done so for a long time in the past and those at increased risk of cancer. For those ...
Developed by specialists from the medical, technology, and design fields, the platform aims to establish a culture of preventative healthcare in Latvia as well as educate women on breast cancer risks and contraception methods. By educating more individuals and collecting real-world data, skrinings.lv is actively contributing to decreasing unwanted pregnancies, ...
Study plans to investigate elinzanetant as non-hormonal treatment for vasomotor symptoms caused by endocrine therapy in breast cancer patients Elinzanetant is an innovative non-hormonal development compound in development for the treatment of vasomotor symptoms during menopause Bayer, a global leader in women’s healthcare, announced today that it expands the ...
ByBayer AG
The ISET® patented EC-marked platform is able to extract down to one single cancer cell of any type from 10 ml of blood, thus a tumor cell mixed with 100 million leukocytes and 50 billion erythrocytes, according to peer-reviewed published studies. ...
Results from this trial were published in the New England Journal of Medicine.1 The ARASENS trial demonstrated that darolutamide plus ADT and docetaxel significantly reduced the risk of death by 32.5% compared to ADT plus docetaxel.1 Improvements in the secondary endpoints supported the OS benefit observed in the trial’s primary endpoint.1 About Metastatic ...
ByBayer AG